Small molecule glutaminase inhibitors block glutamate release from stimulated microglia

Biochemical and Biophysical Research Communications

Volumn 443, Issue 1, 2014, Pages 32-36

  Thomas, Ajit G ^a   O'Driscoll, Cliona M ^b   Bressler, Joseph ^b   Kaufmann, Walter ^b,c   Rojas, Camilo J ^a   Slusher, Barbara S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Glutamate; Glutaminase; Glutamine; HIV associated dementia (HAD); Inflammation; Microglia

Indexed keywords

6 DIAZO 5 OXONORLEUCINE; BIS 2 (5 PHENYLACETIMIDO 1,2,4 THIADIAZOL 2 YL)ETHYL SULFIDE; GLUTAMIC ACID; GLUTAMINASE INHIBITOR; HYDROLASE INHIBITOR; NEUROPROTECTIVE AGENT; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; ENZYME ACTIVITY; ENZYME ANALYSIS; HIV ASSOCIATED DEMENTIA; MACROPHAGE; MICROGLIA; MOLECULE; MULTIPLE SCLEROSIS; NEUROPROTECTION; PRIORITY JOURNAL;

6-DIAZO-5-OXO-L-NORLEUCINE; BIS-2-(5-PHENYLACETIMIDO-1,2,4-THIADIAZOL-2-YL)ETHYL SULFIDE; BPTES; CENTRAL NERVOUS SYSTEM; CNS; CPG OLIGODEOXYNUCLEOTIDE; DON; GC; GLS; GLUTAMATE; GLUTAMINASE; GLUTAMINE; HAD; HIV; HIV-ASSOCIATED DEMENTIA; HIV-ASSOCIATED DEMENTIA (HAD); HORSE RADISH PEROXIDASE; HRP; HUMAN IMMUNODEFICIENCY VIRUS; INFLAMMATION; LIPOPOLYSACCHARIDE; LPS; MICROGLIA; NF-ΚB; NUCLEAR FACTOR-ΚB; PAM3SK4; PHORBOL 12-MYRISTATE 13-ACETATE; PMA; POLY I:C; POLYINOSINIC-POLYCYTIDYLIC; TLR; TNF-Α; TOLL-LIKE RECEPTOR; TRIPALMITOYL-S-GLYCERYL-CYSTEINE; TUMOR NECROSIS FACTOR-Α;

AIDS DEMENTIA COMPLEX; ANIMALS; BIOLOGICAL ASSAY; BRAIN ISCHEMIA; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; GLUTAMIC ACID; GLUTAMINASE; MICE; MICROGLIA; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; SMALL MOLECULE LIBRARIES; TETRADECANOYLPHORBOL ACETATE; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890857120     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.11.043     Document Type: Article

References (34)

1. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007, 8:57-69.
2. Kempermann G., Neumann H. Neuroscience. Microglia: the enemy within?. Science 2003, 302:1689-1690.
3. Perry V.H., Nicoll J.A., Holmes C. Microglia in neurodegenerative disease. Nat. Rev. Neurol. 2010, 6:193-201.
4. Block M.L., Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 2005, 76:77-98.
5. Basith S., Manavalan B., Lee G., Kim S.G., Choi S. Toll-like receptor modulators: a patent review (2006-2010). Expert Opin. Ther. Pat. 2011, 21:927-944.
6. Choi D.K., Koppula S., Suk K. Inhibitors of microglial neurotoxicity: focus on natural products. Molecules 2011, 16:1021-1043.
7. Figuera-Losada M., Rojas C., Slusher B.S. Inhibition of Microglia Activation as a Phenotypic Assay in Early Drug Discovery. J. Biomol. Screen. 2013.
8. Illei G.G., Lipsky P.E. Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases. Curr. Opin. Immunol. 2000, 12:712-718.
9. McCarty M.F. Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders. Med. Hypotheses 2006, 67:251-269.
10. Nakamura Y. Regulating factors for microglial activation. Biol. Pharm. Bull. 2002, 25:945-953.
11. Potter M.C., Figuera-Losada M., Rojas C., Slusher B.S. Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders. J. Neuroimmune Pharmacol. 2013, 8:594-607.
12. Erdmann N., Zhao J., Lopez A.L., Herek S., Curthoys N., Hexum T.D., Tsukamoto T., Ferraris D., Zheng J. Glutamate production by HIV-1 infected human macrophage is blocked by the inhibition of glutaminase. J. Neurochem. 2007, 102:539-549.
13. Shijie J., Takeuchi H., Yawata I., Harada Y., Sonobe Y., Doi Y., Liang J., Hua L., Yasuoka S., Zhou Y., Noda M., Kawanokuchi J., Mizuno T., Suzumura A. Blockade of glutamate release from microglia attenuates experimental autoimmune encephalomyelitis in mice. Tohoku J. Exp. Med. 2009, 217:87-92.
14. Zhao J., Lopez A.L., Erichsen D., Herek S., Cotter R.L., Curthoys N.P., Zheng J. Mitochondrial glutaminase enhances extracellular glutamate production in HIV-1-infected macrophages: linkage to HIV-1 associated dementia. J. Neurochem. 2004, 88:169-180.
15. Takeuchi H., Jin S., Wang J., Zhang G., Kawanokuchi J., Kuno R., Sonobe Y., Mizuno T., Suzumura A. Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J. Biol. Chem. 2006, 281:21362-21368.
16. Pinkus L.M. Glutamine binding sites. Methods Enzymol. 1977, 46:414-427.
17. Shukla K., Ferraris D.V., Thomas A.G., Stathis M., Duvall B., Delahanty G., Alt J., Rais R., Rojas C., Gao P., Xiang Y., Dang C.V., Slusher B.S., Tsukamoto T. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J. Med. Chem. 2012, 55:10551-10563.
18. Gottfried-Blackmore A., Sierra A., Jellinck P.H., McEwen B.S., Bulloch K. Brain microglia express steroid-converting enzymes in the mouse. J. Steroid Biochem. Mol. Biol. 2008, 109:96-107.
19. McElroy K.E., Bouchard P.J., Harpel M.R., Horiuchi K.Y., Rogers K.C., Murphy D.J., Chung T.D., Copeland R.A. Implementation of a continuous, enzyme-coupled fluorescence assay for high-throughput analysis of glutamate-producing enzymes. Anal. Biochem. 2000, 284:382-387.
20. Engler J.A., Gottesman J.M., Harkins J.C., Urazaev A.K., Lieberman E.M., Grossfeld R.M. Properties of glutaminase of crayfish CNS: implications for axon-glia signaling. Neuroscience 2002, 114:699-705.
21. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol. Ther. 1999, 81:163-221.
22. Lau A., Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch. 2010, 460:525-542.
23. Marmiroli P., Cavaletti G. The glutamatergic neurotransmission in the central nervous system. Curr. Med. Chem. 2012, 19:1269-1276.
24. Ghosh T.K., Mickelson D.J., Fink J., Solberg J.C., Inglefield J.R., Hook D., Gupta S.K., Gibson S., Alkan S.S. Toll-like receptor (TLR) 2-9 agonists-induced cytokines and chemokines: I. comparison with T cell receptor-induced responses. Cell. Immunol. 2006, 243:48-57.
25. Schreck R., Rieber P., Baeuerle P.A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 1991, 10:2247-2258.
26. Li C., Wang Y., Gao L., Zhang J., Shao J., Wang S., Feng W., Wang X., Li M., Chang Z. Expression of toll-like receptors 2 and 4 and CD14 during differentiation of HL-60 cells induced by phorbol 12-myristate 13-acetate and 1 alpha, 25-dihydroxy-vitamin D(3). Cell Growth Differ. 2002, 13:27-38.
27. Goldlust A., Su T.Z., Welty D.F., Taylor C.P., Oxender D.L. Effects of anticonvulsant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA. Epilepsy Res. 1995, 22:1-11.
28. Barton G.M., Medzhitov R. Toll-like receptor signaling pathways. Science 2003, 300:1524-1525.
29. Akira S., Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4:499-511.
30. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
31. O'Neill L.A., Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci. 1997, 20:252-258.
32. Kostandy B.B. The role of glutamate in neuronal ischemic injury: the role of spark in fire. Neurol. Sci. 2012, 33:223-237.
33. Brigell M.G., Taylor C.P. ALS defeats gabapentin: reflections on another failed treatment. Neurology 2001, 57:1524-1525.
34. Miller R.G., Moore D.H., Gelinas D.F., Dronsky V., Mendoza M., Barohn R.J., Bryan W., Ravits J., Yuen E., Neville H., Ringel S., Bromberg M., Petajan J., Amato A.A., Jackson C., Johnson W., Mandler R., Bosch P., Smith B., Graves M., Ross M., Sorenson E.J., Kelkar P., Parry G., Olney R. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001, 56:843-848.